SANUWAVE Health, Inc. (SNWV)
| Market Cap | 257.31M |
| Revenue (ttm) | 36.19M |
| Net Income (ttm) | -32.52M |
| Shares Out | 8.55M |
| EPS (ttm) | -5.58 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 48,889 |
| Open | 31.53 |
| Previous Close | 31.55 |
| Day's Range | 29.80 - 31.93 |
| 52-Week Range | 25.23 - 39.50 |
| Beta | 1.25 |
| Analysts | n/a |
| Price Target | n/a |
| Earnings Date | May 8, 2025 |
About SNWV
SANUWAVE Health, Inc. operates as a medical device company in the United States and internationally. It focuses on the commercialization of regenerative medicines through noninvasive ultrasound or shockwaves to produce a biological response promoting the repair and regeneration of tissue, musculoskeletal, and vascular structures. The company markets UltraMist system, a medical device that uses non-thermal ultrasound to treat tissues using a fluid mist to transmit energy in a non-contact and pain free way for use in the treatment of acute and ch... [Read more]
Financial Performance
In 2024, SANUWAVE Health's revenue was $32.63 million, an increase of 59.99% compared to the previous year's $20.40 million. Losses were -$31.37 million, 21.6% more than in 2023.
Financial StatementsNews
Sanuwave Announces Q1 FY2025 Financial Results
Q1 2025 revenues were $9.3 million , up 61% from $5.8 million in Q1 2024. This represents the highest Q1 quarterly revenues in Company history.
Sanuwave Will Host a Conference Call on May 9, 2025 at 8:30 AM (ET) to Present Q1 2025 Financial Results
EDEN PRAIRIE, Minn., May 05, 2025 (GLOBE NEWSWIRE) -- Sanuwave Health, Inc. (the "Company" or "Sanuwave”) (NASDAQ: SNWV), a leading provider of next-generation FDA-approved wound care products, will h...
SANUWAVE Health Announces Preliminary Revenue Results for the First Quarter 2025 (Ended March 31, 2025)
SANUWAVE is pleased to announce preliminary revenues of $9.1 million to $9.3 million for the first quarter ended March 31, 2025. This represents the highest Q1 quarterly revenues in Company history.
SANUWAVE Health, Inc. (SNWV) Q4 2024 Earnings Call Transcript
SANUWAVE Health, Inc. (NASDAQ:SNWV) Q4 2024 Results Conference Call March 21, 2025 8:30 AM ET Company Participants Morgan Frank - Chairman and Chief Executive Officer Peter Sorensen - Chief Financial...
SANUWAVE Announces Record Quarterly Revenues: Q4 FY2024 Financial Results
Q4 2024 revenues were $10.3 million, up 47% from Q4 2023. This was an all-time quarterly record for the Company.
SANUWAVE Will Host a Conference Call on March 21, 2025 at 8:30 AM (ET) to Present Q4 and Full Year 2024 Financial Results
EDEN PRAIRIE, Minn.--(BUSINESS WIRE)--SANUWAVE Health, Inc. (the "Company" or "SANUWAVE”) (NASDAQ: SNWV), a leading provider of next-generation FDA-approved wound care products, will host a live confe...
Sanuwave Health to Uplist to the Nasdaq Global Market
Trading Under the Ticker “SNWV” Expected to Begin on March 7, 2025 Trading Under the Ticker “SNWV” Expected to Begin on March 7, 2025
SANUWAVE Health to Participate in 37th Annual Roth Conference
EDEN PRAIRIE, Minn., Feb. 19, 2025 (GLOBE NEWSWIRE) -- SANUWAVE Health, Inc. (OTCQB: SNWV), a leading provider of next-generation FDA-approved wound care products, today announced that Morgan Frank, C...
SANUWAVE Announces Record Quarterly Revenues: Q3 FY2024 Financial Results
Q3 2024 revenues were $9.4 million, up 89% from Q3 2023. This was an all-time quarterly record for the Company.
SANUWAVE Will Host a Conference Call on November 8, 2024 at 8:30 AM (ET) to Present Q3 Financial Results
EDEN PRAIRIE, Minn., Nov. 04, 2024 (GLOBE NEWSWIRE) -- SANUWAVE Health, Inc. (the "Company" or "SANUWAVE”) (OTCQB: SNWV), a leading provider of next-generation FDA-approved wound care products, will h...
SANUWAVE Health Announces 1-For-375 Reverse Stock Split
Common Stock Will Begin Trading on a Split-adjusted Basis on October 18, 2024 EDEN PRAIRIE, Minn., Oct. 16, 2024 (GLOBE NEWSWIRE) -- SANUWAVE Health, Inc. (the “Company” or “SANUWAVE”) (OTCQB: SNWV), ...
SANUWAVE Health Inc. (SNWV) Q2 2024 Earnings Call Transcript
SANUWAVE Health Inc. (OTCQB:SNWV) Q2 2024 Earnings Conference Call August 13, 2024 8:30 AM ET Company Participants Morgan Frank - Chairman and Chief Executive Officer Peter Sorensen - Chief Financial ...
SANUWAVE Announces Record Quarterly Revenues: Q2 FY2024 Financial Results
Q2 2024 revenues were $7.2 million, up 53% from Q2 2023. This was an all-time quarterly record for the Company.
SANUWAVE Will Host a Conference Call on August 13, 2024 at 8:30 AM (ET) to Present Q2 Financial Results
EDEN PRAIRIE, MN, Aug. 07, 2024 (GLOBE NEWSWIRE) -- SANUWAVE Health, Inc. (the "Company" or "SANUWAVE”) (OTCQB: SNWV), a leading provider of next-generation FDA-approved wound care products, will host...
SANUWAVE Health Announces Preliminary Revenue Results for the First Quarter 2024 (Ended March 31, 2024)
SANUWAVE is pleased to announce preliminary revenues of $5.7 million to $5.9 million for the first quarter ended March 31, 2024. This represents the highest Q1 revenues in company history.
SANUWAVE Health Appoints Industry Veteran Peter Sorensen as Chief Financial Officer
Sorensen brings strong finance, forecasting, analysis, and capital markets experience as well as abilities in software, process automation, and human resources to SANUWAVE
SANUWAVE Health Inc. (SNWV) Q4 2023 Earnings Call Transcript
SANUWAVE Health Inc. (SNWV) Q4 2023 Earnings Call Transcript
SANUWAVE Announces Record Q4 and FY2023 Revenue
Q4 2023 revenues were a record $7.0 million, up 27% from Q4 2022 FY 2023 revenues were a record $20.4 million, up 22% from FY2022 Operating income was $1 million for Q4 2023 compared to an operating l...
SANUWAVE Will Host a Conference Call on March 22, 2024 at 8:30 AM (ET) to Present the Q4 and FY2023 Financial Results
EDEN PRAIRIE, MN, March 20, 2024 (GLOBE NEWSWIRE) -- via NewMediaWire – SANUWAVE Health, Inc. (the "Company" or "Sanuwave”) (OTCQB: SNWV), a leading provider of next-generation FDA-approved wound care...
SANUWAVE Health Reports Stockholder Approval of SEPA Merger at Special Meeting of Stockholders
At a special meeting of stockholders on February 21, 2024, SANUWAVE stockholders approved the business combination with SEP Acquisition Corp. by a vote of 798,379,869 “for” and 5,221,765 “against” wit...
SANUWAVE Announces Special Meeting of Stockholders to Vote on Business Combination with SEP Acquisition Corp. (Nasdaq: SEPA)
EDEN PRAIRIE, MN, Jan. 22, 2024 (GLOBE NEWSWIRE) -- via NewMediaWire – SANUWAVE Health, Inc. (the "Company" or "SANUWAVE”) (OTCQB: SNWV), a leading provider of next-generation FDA-approved wound care...
SANUWAVE Health Announces Preliminary Revenue Results for the Fourth Quarter and Fiscal Year 2023, Ended December 31, 2023
SANUWAVE is pleased to announce preliminary revenues of $6.6 million to $6.8 million for the fourth quarter ended December 31, 2023. This represents a new quarterly revenue record for the Company.
SANUWAVE Announces Q3 2023 Financial Results
EDEN PRAIRIE, MN,, Nov. 10, 2023 (GLOBE NEWSWIRE) -- via NewMediaWire – SANUWAVE Health, Inc. (the “Company” or “SANUWAVE”) (OTCQB: SNWV), a leading provider of next-generation FDA-approved wound care...
SANUWAVE Will Host a Conference Call on November 10, 2023 at 8:00 AM (ET) to Present the Q3 2023 Financial Results
EDEN PRAIRIE, MN, Nov. 08, 2023 (GLOBE NEWSWIRE) -- via NewMediaWire - SANUWAVE Health, Inc. (OTCQB: SNWV), a leading provider of next-generation wound care products, will host a live conference call ...
SANUWAVE Health Announces Preliminary Revenue Results for the Third Quarter Ended September 30, 2023
SANUWAVE is Pleased to Announce Preliminary Revenues of $4.7 Million to $4.9 Million for the Third Quarter Ended September 30, 2023 Results Indicate 13-18% Growth Rate Over Q3 2022 UltraMist Revenues ...